This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
18-75 years of age.
Primary refractory, defined as not having achieved a CR with frontline therapy or having relapsed within 3 months.
Early relapsed (≤ 12 months) after achieving a CR to frontline therapy.
Tumor biopsy positive for CD70 >/= 10% by immunohistochemistry or flow cytometry.
Lymphoma in CR with no measurable sites of disease.
Major surgery <4 weeks prior to first dose of study drug.
Any other severe or uncontrolled disease or condition which might increase the risk associated with study participation.
Any other malignancy known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.
M.D. Anderson Cancer Center
Lead sponsor
Bellicum Pharmaceuticals
Collaborator